Venous Malformation Sclerotherapy in Hyderabad (2026) | Image-Guided Treatment, Procedure, Recovery & Success

Feature

Detail

Treatment Type

Image-guided sclerotherapy — minimally invasive, no major surgical incision

Used For

Low-flow venous malformations — confirmed on Doppler USG and MRI

Imaging Guidance

Ultrasound guidance (primary) ± Fluoroscopy (for complex or deep lesions)

Hospital Stay

Day-care for most patients | Overnight or short stay for complex large VMs

Anaesthesia

Local anaesthesia + IV sedation for most | General anaesthesia for selected complex cases (children, extensive lesions, airway proximity)

Procedure Duration

30–90 minutes per session depending on VM size and complexity

Sessions Required

1 session for very small VMs | 2–5 sessions (at 4–8 week intervals) for most significant VMs | More for large/diffuse lesions

Recovery

1–3 days to light activities | 1–2 weeks before significant swelling resolves | Months for maximum shrinkage

Main Goal

Pain relief, functional improvement, volume reduction, cosmetic improvement — not necessarily complete elimination

Specialist

Interventional Radiologist — trained in image-guided vascular anomaly procedures

Suitable Profile

Why Sclerotherapy Is Appropriate

Symptomatic venous malformation — pain affecting daily life

Pain from VM thrombosis, swelling, or pressure on adjacent structures — the most common primary indication for sclerotherapy. Published series consistently show significant pain improvement in most patients.

Progressive enlargement on serial imaging

A VM that is demonstrably growing on Doppler USG or MRI over time — treatment indicated before further enlargement causes greater functional or cosmetic impact

Functional limitation — reduced range of movement, difficulty swallowing

VMs adjacent to joints limit movement; oropharyngeal VMs affect swallowing or speech. Sclerotherapy reduces VM volume and the functional impairment it causes.

Cosmetic disfigurement — visible deformity causing significant distress

Visible VM causing significant psychosocial impact — particularly facial, lip, or cheek VMs in younger patients

Recurrent painful thrombotic episodes

Recurrent acute intravascular thrombosis causing episodic severe pain — a feature of many larger VMs. Sclerotherapy reduces VM volume and the frequency of thrombotic events.

Small accessible VM as single-session treatment

Some small, well-defined, accessible VMs can be effectively treated in a single sclerotherapy session — a more targeted approach than the staged multi-session protocol required for larger lesions

Adjunct to surgery — pre-operative volume reduction

For VMs that will ultimately require surgical excision, pre-operative sclerotherapy reduces VM blood content and fibroses the channels — making surgical dissection safer and reducing intraoperative blood loss

Not Suitable When

Clinical Reason / Alternative

High-flow arteriovenous malformation (AVM)

Sclerotherapy for venous malformation is specifically designed for low-flow lesions. High-flow AVMs — where arterial blood flows rapidly through the lesion — require embolisation, not sclerotherapy. The distinction is made by Doppler USG.

Active infection at or near the planned injection site

Injecting a sclerosant through infected tissue increases the risk of abscess and systemic infection. Sclerotherapy is deferred until infection is fully resolved.

Pregnancy

Sclerotherapy involves fluoroscopic radiation and sclerosant agents — both contraindicated in pregnancy. Elective sclerotherapy is deferred until after delivery.

Known allergy to the planned sclerosant or contrast agent

An alternative sclerosant can usually be selected if allergy to one agent is known. Allergy to contrast requires pre-medication or fluoroscopy-avoidance technique.

Severe uncorrected coagulopathy

Pre-existing severe bleeding disorder significantly increases haematoma risk after sclerotherapy. Coagulation must be optimised before any procedure.

VM draining directly into a major venous structure without adequate buffering

If the VM drains rapidly and directly into a major venous channel, sclerosant may reflux into the systemic circulation — increasing risk. This is assessed by contrast fluoroscopy before injection.

Very small, completely asymptomatic, stable VM

For entirely asymptomatic, non-progressive, non-cosmetically concerning VMs — treatment risks may not be justified and observation is the appropriate initial management.

When

Why

At Consultation

Bring Doppler USG report/disc | Bring MRI report/disc | Previous treatment records (if any previous sclerotherapy or surgery)

Dr. Garge reviews all prior imaging personally before planning the sclerotherapy session. Pre-treatment MRI is mandatory for treatment planning.

Before Procedure

Blood tests: D-dimer, fibrinogen, FBC, coagulation (PT/INR, APTT, platelets), renal function

D-dimer and fibrinogen assess localised intravascular coagulopathy (LIC) risk. Renal function confirms contrast can be safely administered.

If LIC is Elevated

Low molecular weight heparin (LMWH) therapy — given in the days before the procedure to suppress active LIC

Significant LIC (very elevated D-dimer) increases the risk of coagulopathy flare and haematoma during sclerotherapy. LMWH suppression reduces this risk.

Blood Thinners

Aspirin: usually continued | Warfarin/NOACs: paused as per Dr. Garge's specific instruction — typically 3–5 days before procedure

Warfarin and NOACs increase haematoma risk at the injection site. Haematoma in a VM can be very large — anticoagulation management is important

Fasting

If IV sedation or GA planned: fast from midnight for solid foods; clear fluids up to 4 hours before | If local anaesthesia only: light meal permitted on procedure day

Required for safe sedation or GA administration

Day of Procedure

Comfortable, accessible clothing over the VM area | Bring all imaging discs | Arrange a driver if sedation will be given

Sedation impairs driving — driver required. Imaging needed on the day for real-time reference during the procedure.

Before Start

Written informed consent | IV cannula placed | Pre-procedure antihistamine (for patients with prior contrast reaction history)

IV access for emergency medication. Pre-medication reduces contrast allergy risk for sensitised patients.

Sclerosant

Mechanism of Action

Most Commonly Used For

Sodium Tetradecyl Sulphate Foam (STS Foam)

Detergent-based agent — damages venous endothelium by disrupting cell membrane lipids. Administered as foam (mixed with air or CO2) to increase contact time and surface area within VM channels.

Most VM sclerotherapy in Hyderabad. Excellent safety profile. Effective for a wide range of VM sizes. Less painful than ethanol. Can be used in many anatomical locations.

Absolute Ethanol (100% Alcohol)

Most aggressive sclerosant — causes direct protein denaturation and thrombosis throughout the VM channels. Produces intense endothelial destruction and strong fibrotic response.

Large VMs requiring powerful sclerosis where other agents have failed or where the VM is extensive. Requires very careful dosing and monitoring — higher complication risk. Used under general anaesthesia for most patients.

Bleomycin (Antibiotic-derived)

Causes local inflammatory and fibrosing reaction within the VM channels. Produces slower but progressive fibrosis — useful where other agents are contraindicated.

Superficial cutaneous VMs | VMs in high-risk locations (near skin, near nerves) where the risk of ethanol skin necrosis is unacceptable | Paediatric patients where bleomycin's milder tissue effect profile is preferred.

Polidocanol

Detergent-based sclerosant — similar mechanism to STS but with a milder tissue reaction profile and local anaesthetic effect that reduces procedural pain.

Small to medium VMs | Patients where pain control during injection is a significant consideration | Mucosal VMs where gentler tissue effect is preferred.

Combined agents / Sequential sessions

Different sclerosants may be used in different sessions of a multi-session protocol, or occasionally combined in a single session for targeted treatment of different VM components.

Complex, diffuse, or large VMs — tailored approach based on imaging response assessment between sessions

Anaesthesia Type

When Used for VM Sclerotherapy

Patient Experience

Local anaesthesia only

Small, accessible, superficial VMs in cooperative adult patients. Short procedure duration. Mild sclerosant (STS foam or polidocanol).

Awake and comfortable. Local anaesthetic numbs the skin. Mild discomfort or pressure during needle insertion. Injection of sclerosant may cause brief burning or aching.

Local anaesthesia + IV sedation

Most adult VM sclerotherapy sessions. Moderate-sized VMs. Any location in cooperative adult patients. Absolute ethanol (which is more painful) may warrant sedation even for smaller VMs.

Deeply relaxed — conscious but comfortable throughout. Most patients have minimal memory of the procedure. This is the most common anaesthesia approach at Citi Vascular Centre, KPHB.

General anaesthesia

Children undergoing sclerotherapy | Large, extensive VMs requiring prolonged procedure | VMs in the head, neck, or airway where airway protection is necessary | Patients in whom sedation alone is inadequate

Fully unconscious. Managed by an anaesthetist. Higher anaesthesia-related risk than LA or sedation — but required in specific situations.

Factor

How It Determines Session Number

VM size

Small VMs (< 2–3cm) may respond adequately to 1–2 sessions. Moderate VMs (3–6cm) typically require 2–3 sessions. Large or extensive VMs may require 4–6 or more sessions for adequate volume reduction.

VM extent and tissue depth

Superficial, well-localised VMs are more completely treatable per session than deep, intramuscular, or diffuse VMs. Diffuse VMs — spreading through multiple tissue planes — often require many more sessions for progressive staged treatment.

Sclerosant response

Individual variation in how aggressively the VM responds to each session's sclerosant. MRI at 2–3 months after each session measures the volume reduction achieved and determines whether further treatment is indicated.

Anatomical constraints

VMs in locations adjacent to nerves, the airway, or important vascular structures require more conservative dosing per session — distributing the treatment across more sessions to maintain safety margins

Treatment goal

A patient seeking primarily pain relief may achieve this after fewer sessions than a patient whose goal is maximum cosmetic reduction. Treatment goal discussion at each review session guides the continuation decision.

Timeframe

What to Expect

Day 0 (Procedure Day)

Observation + Discharge

1–4 hours recovery in the procedure suite. Mild-to-moderate pain and swelling at the treated VM site beginning as local anaesthetic wears off. Compression dressing applied. Discharged with analgesics and written instructions.

Day 1–2

Inflammatory Response

The sclerosant-induced inflammatory reaction is at its most active. Swelling, redness, warmth, and pain at the VM site are expected and confirm the therapeutic effect is working. Paracetamol and prescribed NSAIDs manage discomfort.

Days 3–5

Settling

Swelling at its maximum — often larger than the original VM at this stage, which is entirely expected. The VM may feel firmer and more tender than before treatment. This temporary increase is the early inflammatory phase of the sclerosis reaction.

Week 1–2

Gradual Improvement

Swelling begins to reduce. Pain substantially decreases from its peak. Bruising and skin discolouration (common at skin surface) fading. Compression garment worn continuously for limb VMs. Desk work resumable for most patients by Day 5–10.

Weeks 3–6

Volume Reduction Begins

The VM becomes noticeably smaller and softer as fibrosis of the treated channels progresses. Patients often notice the first palpable reduction in VM size during this period. Functional improvement becomes apparent.

Month 2–3

MRI Assessment

Follow-up MRI is performed at 8–12 weeks after each sclerotherapy session to measure objectively the volume reduction achieved. This MRI determines whether further treatment sessions are indicated and guides planning for the next session if needed.

Months 3–6

Maximum Response Per Session

The full volume reduction achievable from one sclerotherapy session is typically complete by 3–6 months. If significant residual VM remains, the next session is planned based on the MRI findings.

Area

What to Do

What to Avoid

Compression dressing/garment

Keep compression dressing in place for first 24–48 hours. Replace with prescribed compression garment (for limb VMs) from Day 2 — wear continuously for 2–4 weeks.

Do not remove compression dressing prematurely — compression is an integral part of treatment, not just wound care.

Pain management

Paracetamol 500–1000mg up to 4 times daily. Prescribed NSAID (ibuprofen, diclofenac) for inflammatory pain. Codeine if prescribed for more severe pain in first 48 hours.

Avoid aspirin for pain (increases bleeding risk). Contact team if pain is severe and not controlled by prescribed analgesics.

Activity

Rest on procedure day. Light activities from Day 2–3. Office work from Day 5–10 depending on location and patient tolerance.

No vigorous physical activity or heavy lifting for 2 weeks. No swimming or soaking the treated area until skin puncture sites are healed (typically 5–7 days).

Swelling

Elevation of treated limb above heart level when resting — significantly reduces post-procedure swelling in the first 3–5 days.

Do not become concerned if swelling appears to increase in the first 3–5 days — this is the expected inflammatory response to the sclerosant and resolves as the treatment takes effect.

Anticoagulation (if prescribed)

Resume blood-thinning medications as per Dr. Garge's specific instruction — typically 24–48 hours after procedure if a standard risk. Patients with significant LIC may need continuing anticoagulation.

Do not restart anticoagulants without Dr. Garge's explicit instruction — timing is important for both haematoma prevention and LIC management.

When to call immediately

Call +91-73375 83901 if: rapidly increasing severe pain | rapidly expanding swelling | high fever (> 38.5°C) | voice change after neck/tongue sclerotherapy | difficulty breathing | spreading skin redness

These are uncommon but require prompt assessment. Do not wait for your follow-up appointment if any of these develop.

Outcome Measure

Published Evidence and Clinical Expectation

Pain improvement

The most consistently reported positive outcome — significant pain reduction is achieved in the majority of patients in published series, often after 2–3 sessions. Pain is the primary outcome in most clinical studies.

Volume reduction

Meaningful volume reduction (> 50%) is achieved in the majority of appropriately selected VMs over a complete treatment course. The degree of reduction per session varies with VM size, type, and sclerosant used. Very large or diffuse VMs may achieve partial but not complete reduction.

Functional improvement

Patients with VMs causing joint restriction, swallowing difficulty, or other functional limitation typically experience meaningful functional improvement commensurate with volume reduction.

Cosmetic improvement

Visible VMs in the face, lip, cheek, and extremities show cosmetic improvement in parallel with volume reduction — though complete disappearance is uncommon for large lesions

Avoiding surgery

Many patients who would otherwise require surgical excision can avoid or defer surgery through sclerotherapy — or have surgery made safer by sclerotherapy-induced volume reduction.

Recurrence and long-term durability

Volume reduction achieved by sclerotherapy is generally durable. Partial recurrence over years is possible — particularly for large or diffuse VMs. Long-term follow-up imaging detects this and allows repeat sclerotherapy as needed.

Complication

Frequency

Severity

Management

Post-procedure pain and swelling

Very common — most patients

Expected

Paracetamol and NSAID. Elevation of treated limb. Settles within 1–2 weeks. This is the expected inflammatory response to treatment.

Bruising and skin discolouration

Common

Cosmetic only

Self-resolving within 2–3 weeks. No active treatment required.

Temporary hardness/firmness of VM

Common

Expected

Reflects the fibrosing process within the treated VM channels. Softens progressively over months as fibrosis matures.

Small haematoma within or adjacent to VM

Uncommon — 5–10%

Minor to moderate

Most resolve spontaneously. Compression and elevation. Rarely requires aspiration.

Skin blistering or superficial ulceration

Uncommon

Moderate — cosmetically significant

Risk is higher with absolute ethanol or when VM is very superficial. Managed with wound dressing. Usually heals without surgery.

Temporary nerve involvement

Uncommon — depends on VM proximity to nerve

Variable — may be significant

Numbness, tingling, weakness in the distribution of an adjacent nerve. Usually transient. Resolves over weeks to months as inflammation subsides.

Permanent nerve injury

Rare (< 1–2%) with experienced operator

Significant

Minimised by careful pre-procedure MRI planning, precise image guidance, and conservative dosing near known nerve locations.

Allergic reaction to sclerosant or contrast

Rare — < 1%

Variable

Antihistamine + steroid if mild. Adrenaline for anaphylaxis (rare). Pre-medication for known contrast sensitivity.

Deep vein thrombosis (DVT)

Rare — more common with large VMs and ethanol sclerotherapy

Potentially significant

Anticoagulation monitoring. LMWH treatment if DVT confirmed on imaging. Risk reduced by pre-procedure LIC management.

Follow-Up Component

What It Involves

Clinical review at 2–4 weeks

Dr. Garge reviews clinical response — pain improvement, VM firmness, skin healing, compression adherence, and any concerns about the recovery. This appointment is included in the standard sclerotherapy package.

MRI at 2–3 months after each session

The most important outcome assessment tool — MRI objectively measures the volume reduction achieved by the most recent sclerotherapy session. Compares with pre-treatment and post-previous-session MRI. Guides the decision whether further sessions are needed.

Doppler ultrasound — selected cases

For superficial or easily accessible VMs, ultrasound follow-up can complement or replace MRI for routine inter-session monitoring. More accessible and less expensive than MRI — but less complete for deep or extensive VMs.

D-dimer monitoring

For patients with large VMs and pre-treatment LIC — D-dimer and fibrinogen are repeated after each session and before each subsequent session to manage anticoagulation and identify coagulopathy risk.

Planning the next session

Based on MRI response, residual symptom burden, and patient preference — Dr. Garge discusses at each follow-up whether a further sclerotherapy session is indicated, and if so, what the approach for the next session will be.

Long-term surveillance

After treatment is complete, annual or biennial clinical review with periodic imaging (MRI or USG) is recommended — particularly for large VMs where late partial recurrence is possible. Long-term surveillance enables early retreatment if recurrence is detected.

Credential / Expertise

Relevance to VM Sclerotherapy

FRCR (UK) — Royal College of Radiologists

Covers both imaging interpretation (MRI and Doppler for VM characterisation) and interventional procedures (image-guided sclerotherapy technique)

FNVIR (CMC Vellore)

India's most prestigious IR fellowship — direct procedural training in image-guided vascular anomaly treatment including VM sclerotherapy

EBIR (Spain/Europe)

CIRSE, which publishes the principal European guidelines and standards of practice for image-guided vascular malformation treatment, is the certifying body for EBIR

ISSVA-aligned practice

All VM management at Citi Vascular Centre uses ISSVA 2018 classification — ensuring appropriate patient selection and the right treatment modality for each VM type

Personal Doppler USG throughout each session

The critical step of confirming low-flow status (ruling out AVM), needle placement confirmation, and post-procedure assessment are all performed personally by Dr. Garge — not by a technician

Fluoroscopy + USG combined guidance

Both imaging modalities are available for each session. Fluoroscopic contrast mapping before sclerosant injection — a key safety step — is standard practice for complex or larger VMs

Multidisciplinary collaboration

Surgical, haematological, paediatric, and plastic surgery input is coordinated for complex or syndromic VMs requiring more than sclerotherapy alone

Credential

Detail

Name

Dr. Shaileshkumar Garge | MBBS | MD (Mumbai) | DNB (Delhi) | FRCR (UK) | FNVIR (CMC Vellore) | EBIR (Spain) | Fellowship (North Carolina, USA)

Role

Director and Chief Vascular Physician | Senior Consultant Vascular and Interventional Radiologist

Centre

Citi Vascular Centre, KPHB Colony, Road No. 1, Hyderabad, Telangana 500072

Experience

12+ years dedicated interventional radiology | 15,000+ minimally invasive image-guided diagnostic and therapeutic procedures

Source

Reference / Guidelins

ISSVA Classification

International Society for the Study of Vascular Anomalies (ISSVA). Classification of Vascular Anomalies. 2018 (revised). issva.org. — The internationally accepted classification placing VMs as low-flow vascular malformations.

SIR Guidelines

Society of Interventional Radiology (SIR). Clinical Practice Guidelines for the Management of Venous Malformations. Available at sirweb.org. — Primary evidence-based framework for image-guided VM sclerotherapy in the USA.

CIRSE Standards

Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Standards of Practice: Sclerotherapy for Venous Malformations. Cardiovasc Intervent Radiol. — Defines current European best practice for image-guided VM sclerotherapy.

STS Foam Evidence

Cabrera J et al. Microfoam sclerotherapy of large venous malformations. Phlebology. Published evidence supporting foam sclerotherapy as an effective agent for venous malformation treatment.

Ethanol Sclerotherapy

Lee BB et al. Absolute ethanol sclerotherapy for venous malformations: assessment of outcomes. J Vasc Interv Radiol. Multiple series demonstrating high efficacy of ethanol sclerotherapy for large VMs with accepted complication profile.

Bleomycin Evidence

Claerebout E et al. Bleomycin sclerotherapy for venous malformations: a systematic review. — Supports bleomycin as effective and well-tolerated option particularly in paediatric and superficial VMs.

LIC Management

Dompmartin A et al. Localised intravascular coagulopathy — clinical implications for sclerotherapy planning and peri-procedural anticoagulation. Dermatol Surg. — Establishes the importance of D-dimer monitoring and LMWH before VM procedures.

VM Sclerotherapy — Image-Guided. Minimally Invasive. Day-Care.

USG + Fluoroscopy | STS / Ethanol / Bleomycin | Staged Treatment | MRI Follow-Up | ISSVA-Aligned

Dr. Shaileshkumar Garge | FRCR (UK) | FNVIR (CMC Vellore) | EBIR (Spain) | 12+ Years | 15,000+ Procedures

Call +91-73375 83901  |  WhatsApp 73375 83901  |  citivascularcentre.com

Citi Vascular Centre, KPHB Colony, Hyderabad | Mon–Sat 9AM–6PM | Outstation Patients Welcome